Next Article in Journal / Special Issue
Evaluation of Cancer Metabolomics Using ex vivo High Resolution Magic Angle Spinning (HRMAS) Magnetic Resonance Spectroscopy (MRS)
Previous Article in Journal
Metabolomic Profiling of Submaximal Exercise at a Standardised Relative Intensity in Healthy Adults
Previous Article in Special Issue
Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information
Article Menu

Export Article

Open AccessReview
Metabolites 2016, 6(1), 10;

Cancer Metabolomics and the Human Metabolome Database

Department of Computing Science, University of Alberta, Edmonton, AB T6G 2E8, Canada
Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E8, Canada
National Institute for Nanotechnology, 11421 Saskatchewan Drive, Edmonton, AB T6G 2M9, Canada
Author to whom correspondence should be addressed.
Academic Editors: Claudiu T. Supuran and Natalie Serkova
Received: 1 December 2015 / Revised: 23 February 2016 / Accepted: 25 February 2016 / Published: 2 March 2016
(This article belongs to the Special Issue Cancer Metabolomics 2016)
Full-Text   |   PDF [3181 KB, uploaded 2 March 2016]   |  


The application of metabolomics towards cancer research has led to a renewed appreciation of metabolism in cancer development and progression. It has also led to the discovery of metabolite cancer biomarkers and the identification of a number of novel cancer causing metabolites. The rapid growth of metabolomics in cancer research is also leading to challenges. In particular, with so many cancer-associate metabolites being identified, it is often difficult to keep track of which compounds are associated with which cancers. It is also challenging to track down information on the specific pathways that particular metabolites, drugs or drug metabolites may be affecting. Even more frustrating are the difficulties associated with identifying metabolites from NMR or MS spectra. Fortunately, a number of metabolomics databases are emerging that are designed to address these challenges. One such database is the Human Metabolome Database (HMDB). The HMDB is currently the world’s largest and most comprehensive, organism-specific metabolomics database. It contains more than 40,000 metabolite entries, thousands of metabolite concentrations, >700 metabolic and disease-associated pathways, as well as information on dozens of cancer biomarkers. This review is intended to provide a brief summary of the HMDB and to offer some guidance on how it can be used in metabolomic studies of cancer. View Full-Text
Keywords: cancer metabolomics; Human Metabolome Database (HMDB); metabolomics databases; oncometabolites; biomarkers cancer metabolomics; Human Metabolome Database (HMDB); metabolomics databases; oncometabolites; biomarkers

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Wishart, D.S.; Mandal, R.; Stanislaus, A.; Ramirez-Gaona, M. Cancer Metabolomics and the Human Metabolome Database. Metabolites 2016, 6, 10.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top